Tirzepatide


Overview

Tirzepatide (Mounjaro, Zepbound) is a dual GIP/GLP-1 receptor agonist that took the crown from semaglutide as the most effective approved weight-loss medication. The SURMOUNT-1 trial showed average weight loss of up to 22.5% at the highest dose — numbers that begin to rival bariatric surgery.

Like semaglutide, it is a real, FDA-approved prescription medication with extensive human trial data.

How It Works

Tirzepatide activates both the GLP-1 receptor (like semaglutide) and the GIP receptor. GIP (glucose-dependent insulinotropic polypeptide) was long considered a minor player, but the dual agonism appears synergistic: greater appetite suppression, greater insulin sensitivity, and possibly improved fat metabolism compared to GLP-1 alone.

Why dual beats single

Head-to-head data (SURPASS-2) showed tirzepatide producing greater weight loss and HbA1c reduction than semaglutide 1 mg. The GIP component may also reduce the nausea burden at equivalent efficacy, though individual response varies.

Key Benefits

Weight loss — up to 22.5% average body weight reduction at 15 mg in trials, the best approved result to date.

Diabetes control — superior HbA1c reductions versus semaglutide, insulin and other comparators.

Sleep apnea — approved for obstructive sleep apnea in obesity after the SURMOUNT-OSA trials.

Cardiometabolic markers — improvements in blood pressure, lipids and liver fat.

Side Effects & Considerations

The side effect profile mirrors semaglutide: gastrointestinal symptoms dominate (nausea, diarrhea, vomiting, constipation), mostly during titration. The same boxed warning for thyroid C-cell tumors applies, with the same MEN2/MTC contraindications.

Same structural issues

Lean mass loss of 25-40% of total weight lost makes protein intake and resistance training essential. Weight regain after discontinuation is the rule. And the grey-market research peptide version carries the same purity, dosing and legality problems — this is a medication with a real, regulated supply chain; use it.

Dosage protocols

Protocol Dosage Frequency Duration Notes
Approved titration (Zepbound) 2.5 mg weekly, escalating every 4+ weeks Once weekly subcutaneous Chronic therapy Titration: 2.5 → 5 → 7.5 → 10 → 12.5 → 15 mg. Prescription only — follow the prescribing physician.

Warnings

Prescription medication. Same thyroid carcinoma contraindications as semaglutide. Resistance training and protein are mandatory to limit muscle loss.